What patent did Firebrick Pharma (ASX:FRE) secure in New Zealand?

Firebrick Pharma has been granted a composition patent in New Zealand for its Nasodine nasal spray. The patent, titled "Improved Virucidal Formulations," protects the unique pharmaceutical formulation itself, rather than just a specific method of using it.

How long does the new patent protect Firebrick Pharma (ASX:FRE) in New Zealand?

The newly approved intellectual property extends Firebrick Pharma's proprietary formulation protection and commercial runway in New Zealand until June 2041. This provides the company with a long-term monopoly on its specific nasal spray formulation within the country.

What is Firebrick Pharma’s (ASX:FRE) share price following this announcement?

At the time of reporting, Firebrick Pharma's share price was $0.042. Given this micro-cap valuation, the stock remains highly speculative, meaning regulatory and patent news can lead to significant short-term price volatility for retail traders.

What medical conditions does Firebrick Pharma’s (ASX:FRE) new patent cover?

The patent covers the therapeutic use of the formulation to treat viral infections, reduce mucous secretions, lower viral load, and shorten the duration of viral presence. By doing so, it aims to prevent secondary illnesses such as sinusitis, bronchitis, and otitis media (middle ear infections).

Where else does Firebrick Pharma (ASX:FRE) hold or seek patent protection for Nasodine?

Firebrick Pharma has already secured this composition patent in Australia and South Africa. It is currently targeting global expansion, with patent applications pending in high-value international markets including the United States, Europe, Canada, Brazil, Israel, Mexico, the Philippines, Singapore, and Hong Kong.

Image for illustrative purposes only. Not a real photo.

Firebrick Pharma secures key New Zealand patent

Q: What makes the Nasodine formulation different from standard povidone-iodine solutions?

The core invention underpins a formulation that shows markedly enhanced virucidal (virus-killing) activity at rapid, clinically relevant exposure times of two and five minutes. It significantly outperforms standard povidone-iodine solutions that have concentrations between 0.5% and 1.0%.

Written by Mahathir BayenaPublished Jun 3, 2026, 2:46 AM

Firebrick Pharma (ASX:FRE) said its patent covering the composition of Nasodine nasal spray has been granted in New Zealand.

The newly approved intellectual property extends the company’s proprietary formulation protection and commercial runway in the region until June 2041.

The core invention underpins Nasodine's specific formulation, which demonstrates markedly enhanced virucidal activity at clinically relevant exposure times of two and five minutes when compared directly to standard povidone-iodine solutions ranging between 0.5% and 1.0%.

The patent covers the therapeutic use of this formulation for treating viral infections, reducing mucous secretions, lowering viral load, and minimising the duration of viral presence to prevent secondary illnesses like sinusitis, bronchitis, and otitis media.

While the composition patent is already secured in Australia and South Africa, it remains pending across multiple high-value international markets, including the United States, Europe, Canada, Brazil, Israel, Mexico, the Philippines, Singapore, and Hong Kong.

According to Firebrick Executive Chairman Dr Peter Molloy, the broad composition approval represents a pivotal asset for the Nasodine patent family, as it protects the core pharmaceutical formulation irrespective of its specific intended clinical use.

At the time of reporting, Firebrick Pharma’s share price was $0.042.